Skip to main content

Blood-Derived Products Under Evaluation for the Treatment of COVID-19

Last Updated: July 17, 2020

Summary Recommendations
Summary Recommendations
  • There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of the following blood-derived products for the treatment of COVID-19:
    • COVID-19 convalescent plasma
    • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins
  • The Panel recommends against the use of the following blood-derived products for the treatment of COVID-19, except in a clinical trial:
    • Mesenchymal stem cells (AII)
    • Non-SARS-CoV-2-specific intravenous immunoglobulin (IVIG) (AIII). This recommendation should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of COVID-19.
Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies; III = Expert opinion